NEWS , Press release 2023.6.6 Rebirthel signs Strategic Alliance Agreement with H.U. Group Research Institute G.K. to develop next-generation immune cell therapy based on Rebirthel’s patented technology to produce universal allogeneic T cells

Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic alliance agreement with H.U. Group Research Institute G.K. (H.U. Group) on April 1, 2023 to develop next-generation immune cell therapy based on Rebirthel’s technology to produce universal allogenic T cell.
For details, please refer to the attached press release.